SCHEMBL4077449

SCHEMBL4077449

COc1ccc(CN(Cc2cc3cccc(C)c3[nH]c2=O)S(=O)(=O)c2ccccc2)cc1

nearest known ligand 0.62

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 8/20 0.62
ALDH1A1 P00352 7/20 0.59
HSD17B10 Q99714 4/20 0.59
LMNA P02545 4/20 0.59
MAPT P10636 2/20 0.59
ALOX12 P18054 1/20 0.59
APOBEC3A P31941 1/20 0.58
APOBEC3G Q9HC16 1/20 0.58
HPGD P15428 4/20 0.57
TAS2R14 Q9NYV8 3/20 0.56
KMT2A Q03164 2/20 0.55
TSHR P16473 2/20 0.55
MEN1 O00255 1/20 0.55
SMN1; SMN2 Q16637 2/20 0.52
ATM Q13315 1/20 0.52
RXFP1 Q9HBX9 1/20 0.52
THRB P10828 1/20 0.51
ALOX15 P16050 1/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4074094 0.84 KDM4E (0.61) KDM4EALDH1A1HSD17B10LMNAMAPT
SCHEMBL4071631 0.84 KDM4E (0.70) KDM4EALDH1A1HSD17B10LMNAMAPT
SCHEMBL4080463 0.83 KDM4E (0.58) KDM4EALDH1A1HSD17B10LMNAMAPT
SCHEMBL4074624 0.83 KDM4E (0.60) KDM4EALDH1A1HSD17B10LMNAMAPT
SCHEMBL4081531 0.81 KDM4E (0.59) KDM4EALDH1A1HSD17B10LMNAMAPT
SCHEMBL4070694 0.80 KDM4E (0.64) KDM4EALDH1A1HSD17B10LMNAMAPT
SCHEMBL4078112 0.79 KDM4E (0.58) KDM4EALDH1A1HSD17B10LMNAHPGD
SCHEMBL4069446 0.79 ALDH1A1 (0.74) KDM4EALDH1A1HSD17B10LMNAALOX12
SCHEMBL4072759 0.78 ALDH1A1 (0.60) KDM4EALDH1A1HSD17B10LMNAMAPT
SCHEMBL2445958 0.77 TAS2R14 (0.82) TAS2R14

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2040711-A2 2-OXO-1,2-DIHYDROQUINOLINE DERIVATIVES, COMPOSITIONS, AND USES THEREOF AS ANTIPROLIFERATIVE AGENTS Amphora Discovery Corporation (US) 2009-04-01 EP claimed
US-20070287706-A1 Certain substituted quinolones, compositions, and uses thereof AGRIUS GROUP, LLC. 2007-12-13 US claimed
WO-2007136592-A2 2-0X0-L,2-DIHYDR0QUIN0LINE DERIVATIVES, COMPOSITIONS, AND USES THEREOF AS ANTIPROLIFERATIVE AGENTS AMPHORA DISCOVERY CORPORATION (US) 2007-11-29 WO claimed
EP-2040711-A2 2-OXO-1,2-DIHYDROQUINOLINE DERIVATIVES, COMPOSITIONS, AND USES THEREOF AS ANTIPROLIFERATIVE AGENTS Amphora Discovery Corporation (US) 2009-04-01 EP disclosed
US-20070287706-A1 Certain substituted quinolones, compositions, and uses thereof AGRIUS GROUP, LLC. 2007-12-13 US disclosed
WO-2007136592-A2 2-0X0-L,2-DIHYDR0QUIN0LINE DERIVATIVES, COMPOSITIONS, AND USES THEREOF AS ANTIPROLIFERATIVE AGENTS AMPHORA DISCOVERY CORPORATION (US) 2007-11-29 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070287706-A1 Certain substituted quinolones, compositions, and uses thereof ABCG2, ATP5ME, ATP5MG KDM4E 2403/4885ALDH1A1 1055/4885HSD17B10 1580/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.